DIVA Laboratories, Ltd. (TPEX:4153)
Taiwan · Delayed Price · Currency is TWD 40.65
0.00 (0.00%)
Aug 14, 2025, 1:30 PM CST
Achilles Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 859.02 | 862.32 | 893.84 | 949.2 | 712.23 | 736.93 | Upgrade |
Revenue Growth (YoY) | 0.17% | -3.53% | -5.83% | 33.27% | -3.35% | 2.90% | Upgrade |
Cost of Revenue | 592.57 | 602.14 | 643.07 | 683.07 | 530.64 | 523.26 | Upgrade |
Gross Profit | 266.45 | 260.18 | 250.77 | 266.13 | 181.6 | 213.66 | Upgrade |
Selling, General & Admin | 83.64 | 85.71 | 85.01 | 97.7 | 88.18 | 83.1 | Upgrade |
Research & Development | 71.31 | 71.9 | 69.16 | 82.62 | 69.52 | 61.58 | Upgrade |
Other Operating Expenses | 0.7 | 0.28 | -2.17 | 0.46 | -0.18 | -1 | Upgrade |
Operating Expenses | 155.68 | 149.01 | 158.62 | 181.3 | 158.99 | 143.13 | Upgrade |
Operating Income | 110.76 | 111.17 | 92.15 | 84.83 | 22.6 | 70.54 | Upgrade |
Interest Expense | -0.15 | -0.21 | -0.33 | -0.2 | -0.11 | -0.06 | Upgrade |
Interest & Investment Income | 6.02 | 5.8 | 4.37 | 0.76 | 0.53 | 3.98 | Upgrade |
Earnings From Equity Investments | 0.49 | 1.71 | -7.16 | -1.03 | 2.16 | 1.09 | Upgrade |
Currency Exchange Gain (Loss) | -1.28 | -1.28 | -17.07 | -2.14 | -11.16 | -22.28 | Upgrade |
Other Non Operating Income (Expenses) | 0.58 | 4.9 | 6.66 | 8.39 | 11.15 | 8.26 | Upgrade |
EBT Excluding Unusual Items | 116.43 | 122.09 | 78.63 | 90.62 | 25.18 | 61.52 | Upgrade |
Impairment of Goodwill | - | - | - | -5.18 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -6.14 | -6.14 | 9.21 | -17.34 | 0.44 | -33.98 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.07 | 0.93 | 2.85 | 0.01 | Upgrade |
Asset Writedown | - | - | - | -1.38 | - | - | Upgrade |
Pretax Income | 110.29 | 115.95 | 87.77 | 67.64 | 28.47 | 27.56 | Upgrade |
Income Tax Expense | 21.35 | 22.29 | 14.15 | 17.98 | 6.61 | 10.14 | Upgrade |
Net Income | 88.94 | 93.66 | 73.62 | 49.66 | 21.86 | 17.42 | Upgrade |
Net Income to Common | 88.94 | 93.66 | 73.62 | 49.66 | 21.86 | 17.42 | Upgrade |
Net Income Growth | -7.21% | 27.23% | 48.24% | 127.23% | 25.47% | -68.92% | Upgrade |
Shares Outstanding (Basic) | 59 | 59 | 59 | 59 | 59 | 66 | Upgrade |
Shares Outstanding (Diluted) | 59 | 59 | 59 | 59 | 59 | 67 | Upgrade |
Shares Change (YoY) | -0.01% | 0.03% | 0.13% | 0.07% | -11.69% | 10.51% | Upgrade |
EPS (Basic) | 1.52 | 1.60 | 1.25 | 0.85 | 0.37 | 0.26 | Upgrade |
EPS (Diluted) | 1.51 | 1.59 | 1.25 | 0.84 | 0.37 | 0.26 | Upgrade |
EPS Growth | -7.32% | 27.20% | 48.81% | 127.03% | 42.31% | -72.12% | Upgrade |
Free Cash Flow | 108.05 | 121.63 | 245.43 | 62.84 | -23.53 | -37.4 | Upgrade |
Free Cash Flow Per Share | 1.83 | 2.06 | 4.17 | 1.07 | -0.40 | -0.56 | Upgrade |
Dividend Per Share | 2.000 | 2.000 | 1.250 | 1.000 | 0.370 | 0.260 | Upgrade |
Dividend Growth | 60.00% | 60.00% | 25.00% | 170.27% | 42.31% | - | Upgrade |
Gross Margin | 31.02% | 30.17% | 28.06% | 28.04% | 25.50% | 28.99% | Upgrade |
Operating Margin | 12.89% | 12.89% | 10.31% | 8.94% | 3.17% | 9.57% | Upgrade |
Profit Margin | 10.35% | 10.86% | 8.24% | 5.23% | 3.07% | 2.36% | Upgrade |
Free Cash Flow Margin | 12.58% | 14.11% | 27.46% | 6.62% | -3.30% | -5.08% | Upgrade |
EBITDA | 117.88 | 118.67 | 100.32 | 93.06 | 34.05 | 86.03 | Upgrade |
EBITDA Margin | 13.72% | 13.76% | 11.22% | 9.80% | 4.78% | 11.67% | Upgrade |
D&A For EBITDA | 7.12 | 7.5 | 8.17 | 8.23 | 11.44 | 15.49 | Upgrade |
EBIT | 110.76 | 111.17 | 92.15 | 84.83 | 22.6 | 70.54 | Upgrade |
EBIT Margin | 12.89% | 12.89% | 10.31% | 8.94% | 3.17% | 9.57% | Upgrade |
Effective Tax Rate | 19.36% | 19.22% | 16.12% | 26.58% | 23.23% | 36.79% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.